rs758100382
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_001930.4(DHPS):āc.518A>Gā(p.Asn173Ser) variant causes a missense change. The variant allele was found at a frequency of 0.0000948 in 1,614,054 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Genomes: š 0.000053 ( 0 hom., cov: 32)
Exomes š: 0.000099 ( 0 hom. )
Consequence
DHPS
NM_001930.4 missense
NM_001930.4 missense
Scores
5
5
9
Clinical Significance
Conservation
PhyloP100: 4.88
Genes affected
DHPS (HGNC:2869): (deoxyhypusine synthase) This gene encodes a protein that is required for the formation of hypusine, a unique amino acid formed by the posttranslational modification of only one protein, eukaryotic translation initiation factor 5A. The encoded protein catalyzes the first step in hypusine formation by transferring the butylamine moiety of spermidine to a specific lysine residue of the eukaryotic translation initiation factor 5A precursor, forming an intermediate deoxyhypusine residue. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, May 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 19-12679696-T-C is Pathogenic according to our data. Variant chr19-12679696-T-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 560194.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr19-12679696-T-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
DHPS | NM_001930.4 | c.518A>G | p.Asn173Ser | missense_variant | 4/9 | ENST00000210060.12 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
DHPS | ENST00000210060.12 | c.518A>G | p.Asn173Ser | missense_variant | 4/9 | 1 | NM_001930.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152170Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
8
AN:
152170
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000557 AC: 14AN: 251482Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135916
GnomAD3 exomes
AF:
AC:
14
AN:
251482
Hom.:
AF XY:
AC XY:
8
AN XY:
135916
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000992 AC: 145AN: 1461884Hom.: 0 Cov.: 32 AF XY: 0.000105 AC XY: 76AN XY: 727242
GnomAD4 exome
AF:
AC:
145
AN:
1461884
Hom.:
Cov.:
32
AF XY:
AC XY:
76
AN XY:
727242
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000526 AC: 8AN: 152170Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74336
GnomAD4 genome
AF:
AC:
8
AN:
152170
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74336
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
11
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Neurodevelopmental disorder with seizures and speech and walking impairment Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 22, 2020 | The DHPS c.518A>G (p.Asn173Ser) variant is a missense variant, which has been identified in a compound heterozygous state in at least five individuals with neurodevelopmental disorder from four unrelated families (Ganapathi et al. 2019). The p.Asn173Ser variant is reported at a frequency of 0.000116 in the European (non-Finnish) population in the Genome Aggregation Database (version 2.1.1). Functional studies demonstrate that the p.(Asn173Ser) variant exhibited partial enzymatic activity, ranging from 18% to 25% of that of wild-type DHPS resulting in impaired biosynthesis of deoxyhypusine (Ganapathi et al. 2019). Based on the collective evidence the c.518A>G (p.Asn173Ser) variant is classified as pathogenic for neurodevelopmental disorder with seizures and speech and walking impairment. - |
Likely pathogenic, criteria provided, single submitter | curation | SIB Swiss Institute of Bioinformatics | Oct 22, 2019 | This variant is interpreted as Likely pathogenic for Neurodevelopmental disorder with seizures and speech and walking impairment, autosomal recessive. The following ACMG Tag(s) were applied: PM2, PP3, PP1, PM3, PS3-Moderate. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 24, 2019 | - - |
DHPS-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 21, 2023 | The DHPS c.518A>G variant is predicted to result in the amino acid substitution p.Asn173Ser. This variant was reported in the compound heterozygous state, in trans with a predicted loss-of-function variant, in all five affected individuals described in the DHPS index study (Ganapathi et al 2019. PubMed ID: 30661771). This variant is reported in 0.012% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/19-12790510-T-C). This variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 05, 2022 | In vitro assays demonstrate N173S loss of function (Ganapathi M, 2019); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; In-silico analysis is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; This variant is associated with the following publications: (PMID: 30661771, 34273022) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
T;.;.;.;T;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;D;D;D;D
M_CAP
Benign
D
MetaRNN
Uncertain
D;D;D;D;D;D
MetaSVM
Benign
T
MutationAssessor
Pathogenic
M;M;.;.;.;.
MutationTaster
Benign
D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;.;.;.;.
REVEL
Uncertain
Sift
Benign
D;D;.;.;.;.
Sift4G
Benign
T;T;T;T;.;D
Polyphen
P;P;.;.;.;.
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at